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The impressive potential of biologics has been demonstrated in psoriasis, hidradenitis
suppurativa, and urticaria. Numerous biologicals are entering the field for a restricted
number of skin disorders. Off-label use of biologics in other recalcitrant skin diseases
has increased. Mounting data point to the potential of already existing biologics
acting on the IL-17/IL-23 pathway in skin disorders with epidermal hyperkeratosis
(e.g., pityriasis rubra pilaris), acneiform inflammation (e.g., hidradenitis suppurativa),
and loss of mucosal integrity (e.g., aphthosis). TNF-α blockers are also effective in
the latter conditions but seem of particular value in granulomatous (e.g., granuloma
annulare) and neutrophilic disorders (e.g., pyoderma gangrenosum). Failure of IL-17
blockade in skin diseases resulting from immune-mediated cell destruction (e.g.,
alopecia areata and vitiligo) illustrates its limited involvement in Th1-dependent skin
immunology. Overall, disappointing results of TNF-α blockers in alopecia areata and
vitiligo point to the same conclusion although promising results in toxic epidermal
necrolysis suggest TNF-α exerts at least some in vivo Th1-related activities. Acting
on both the Th1 and Th17 pathway, ustekinumab has a rather broad potential with
interesting results in lupus and alopecia areata. The efficacy of omalizumab in bullous
pemphigoid has revealed an IgE-mediated recruitment of eosinophils leading to bullae
formation. Reconsidering reimbursement criteria for less common but severe diseases
seems appropriate if substantial evidence is available (e.g., pityriasis rubra pilaris). For
other disorders, investigator- and industry-initiated randomized clinical trials should be
stimulated. They are likely to improve patient outcome and advance our understanding
of challenging skin disorders.
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INTRODUCTION
A large number of dermatological disorders is mediated by a deregulated skin immune
response. In the last 2 decades, biologics have revolutionized the traditional approach by
achieving unprecedented results with limited adverse events. Unfortunately, their use is restricted
to a very small number of diseases (psoriasis, urticaria, and hidradenitis suppurativa). The promise
of a targeted approach triggers clinicians to test these drugs in recalcitrant disorders despite their
off-label status. More than 100 articles have been published on the off-label use of biologics. This
is in obvious contrast with the limited number of prospective randomized trials that have been
carried out. In this review we summarize the evidence of the currently available biologics targeting
IL-1, IL-12/IL-23, IL-17, IL-23, TNF-α, CD20, and IgE in different “off-label” skin conditions
(Supplementary Table S1).
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DISORDERS BASED ON TARGETED
IMMUNE-BASED CELL DESTRUCTION:
ALOPECIA AREATA AND VITILIGO
Given the role of TNF-α in the Th1 response, it made sense to
test TNF-α inhibitors in alopecia areata and vitiligo. Nonetheless,
adalimumab fails to induce hair regrowth in most alopecia
areata patients (1). Several cases have been published mentioning
de novo development of alopecia areata due to TNF-α blockers (2,
3). However, some successful cases have also been reported (4).
The risk of vitiligo is significantly increased in patients receiving
this class of biologics [hazard ratio: 1.99 (95% confidence interval:
1.06–3.75)] (5). Overall, repigmentation using TNF-α blockers
is limited in vitiligo and this approach was considered to be
ineffective (6). Nonetheless, TNF-α inhibitors can be useful to
halt disease progression in active vitiligo (7). No data on the
combination of TNF-α inhibitors and phototherapy are available.
Increased IL-17 levels and Th17 lymphocytes have been
observed in the skin and blood of patients with alopecia
areata and vitiligo (8, 9). Unfortunately, most alopecia areata
patients did not show any response to secukinumab, an anti-IL17
monoclonal antibody (10). The same result was observed in our
trial using secukinumab in progressive vitiligo which showed that
7/8 patients developed new skin depigmentations leading to an
early halt of further recruitment. In subsequent experiments, we
showed that Th17.1 cells rather than Th17 cells are increased
in active vitiligo (11). Th17.1 lymphocytes are a subgroup of
Th17 cells gradually differentiating into non-classical Th1 cells.
IL-12 and IL-23 (in combination with low TGF-β) are the main
cytokines driving Th17 > Th1 polarization. In that regard,
ustekinumab, a combined anti-IL12/23 monoclonal antibody,
might represent an attractive treatment option. Despite some
reports mentioning new onset vitiligo and alopecia areata during
ustekinumab, cases showing repigmentation have been published
(12). In alopecia areata, some impressive cases of hair regrowth
following the initiation of ustekinumab illustrate the interesting
potential of this biologic (13, 14). Increased serum levels of IL-23
have been found in vitiligo although no clinical data are available
for IL-23 blockers (15).
ACNEIFORM DISORDERS WITH
NEUTROPHILS: HIDRADENITIS
SUPPURATIVA AND ACNE CONGLOBATA
The introduction of TNF-α blockers in the therapeutic arsenal of
hidradenitis suppurativa has increased the scientific interest for
this disorder. The improvement of abscesses and pustules with
beneficial effects on the quality of life are clear although treatment
failure is more common compared to psoriasis (16).
IL-17 is considered to be an important factor in the
detrimental inflammatory responses in HS. Case reports and
a small pilot trial mention clear improvement in HS patients
receiving secukinumab (17, 18). In contrast, an ex vivo study
on lesional skin samples showed a more pronounced decrease
in pro-inflammatory cytokine production and antimicrobial
peptides with TNF-α inhibitors compared to IL-17 inhibition
(19). Treatment with ustekinumab leads to moderate-marked
responses in 82% of HS patients (20). In a retrospective analysis,
guselkumab showed improvement in 8/11 (73%) of HS patients
(21, 22).
In a small randomized controlled trial (RCT) (10:10),
anakinra—a recombinant IL-1 receptor antagonist—displayed
promising results with a 67% decreased activity score compared
to 20% in the placebo arm (23). Nonetheless, some HS patients
fail to improve with both anakinra and canakinumab (=
monoclonal antibody against IL-1β) (24, 25). Up till now, large
RCTs are missing.
Acne conglobata can be a disfiguring disease with limited
treatment options in case of failure of systemic retinoids. Sand
and Thomsen reported benefit from TNF-α inhibitors in 64%
(7/11) of patients with severe refractory acne conglobata (26).
Propionibacterium acnes stimulates keratinocytes to produce IL-
1α and TNF-α. Additionally, peripheral blood mononuclear cells
(PBMCs) of acne patients stimulated with P. acnes produce
increased amounts of TNF-α and IL-8 pointing to the central role
of TNF-α in this condition (27). P. acnes also promotes Th17 and
Th17.1 responses (28) although no data have been published on
the efficacy of IL-17 blockers or ustekinumab.
SYSTEMIC DISORDERS: LUPUS AND
DERMATOMYOSITIS
A phase II RCT of patients with active systemic lupus
erythematosus (SLE) demonstrated that the addition of
ustekinumab to standard care resulted in an improved efficacy
(29). After 6 months, a Systemic Lupus Erythematosus
Responder Index (SRI)-4 response was achieved in 62% of
ustekinumab treated patients compared to 33% in the placebo
group. Although some patients have been reported to exhibit
lupus-like cutaneous disorders following ustekinumab, several
successfully treated cases of subacute and discoid cutaneous
lupus can be found in literature with ustekinumab (30–32).
Regarding TNF-α blockers, lupus is a well-known adverse event
which can display diverse presentation patterns (33).
Rituximab showed promising results in open-label studies
but failed to reach the primary endpoints in 2 RCTs (34,
35). However, some confounding factors such as concomitant
immunosuppressive medication and problems in study design
(e.g., outcome measures with limited sensitivity) might have
played a role. Nonetheless, cutaneous lesions of SLE showed
beneficial results in a retrospective study. At 6 months, 76%
of patients (n = 50) showed improvement in mucocutaneous
lesions with 40% complete responses. The response to rituximab
in subacute cutaneous lupus erythematosus and chronic
cutaneous lupus erythematosus seems more variable (36).
Omalizumab was tested in a small RCT (n = 15) which
enrolled SLE patients with increased levels of IgE anti-dsDNA,
anti-Sm or anti-SSA autoantibodies. A significant improvement
in Systemic Lupus Erythematosus Disease Activity Index 2000
(SLEDAI-2k) scores was found at 16 weeks although the
difference was lower than the clinically minimal important
change (37).
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A similar pattern emerges with anti-TNF-α antibodies in
dermatomyositis which can develop during therapy. Nonetheless,
an RCT demonstrated that infliximab can be of value in a
subset of patients despite failure to reach the endpoints after 16
weeks (38).
In a retrospective series of patients with refractory idiopathic
inflammatory myopathies (including antisynthetase syndrome,
dermatomyositis and polymyositis) rituximab resulted in a
significantly decreased dependency on glucocorticoids and
favorable clinical responses (39).
Abnormal IL-1 receptor antagonist production has been
observed in dermatomyositis and polymyositis. 4/15 (36.4%)
patients with dermatomyositis or polymyositis improved with
anakinra (40).
APHTHOSIS (AND BEHCET’S SYNDROME)
Anti-TNF-α inhibitors were useful in resistant cases of recurrent
aphthous stomatitis. Adalimumab, etanercept and infliximab
have all shown good efficacy. Complete responses have been
documented in approximately two-thirds of patients treated with
adalimumab (41). Adalimumab is also effective to reduce other
manifestations of Behcet’s syndrome including the resolution of
venous thrombosis (42).
Secukinumab showed benefit in five patients with Behcet’s
syndrome (and concomitant ankylosing spondylitis or psoriatic
arthritis) refractory to conventional treatment and anti-TNF-α
therapy. Improvement of active mucocutaneous manifestations
was evident. Especially the rapid resolution of oral ulcerations
was remarkable (43). Different studies have confirmed the
involvement of IL-17 in the pathogenesis. Ustekinumab was also
effective in a small prospective study of 14 patients. After 12
weeks, complete response was seen in 64%, partial response in
21% with 14% non-responders (44).
IL-1 antagonism (Anakinra) is mainly tested on uveitis in
Behcet’s syndrome although a small pilot study has investigated
the effect on themucocutaneous complaints. In five of six patients




Infliximab is the only biologic with an RCT for classic PG
showing improvement in 20/29 patients (46). Etanercept and
adalimumab have variable efficacy in small studies. Paradoxical
new onset PG has also been linked to TNF-α inhibitors. Beneficial
results have been ascribed to ustekinumab in case reports (47).
This is in line with the role of the IL-17/23 pathway in neutrophil
migration (48). A retrospective study found complete responses
for infliximab in 63.6% (n = 33), for adalimumab in 57.1% (n
= 28), for etanercept in 71.4% (n = 7) and for ustekinumab
in 66.6% (n = 9) of patients. These results were all superior to
corticosteroids (48.8%; n= 78) (49). Anakinra and canakinumab
lead to variable outcomes (50, 51).
Occurrence of Sweet syndrome is possible during anti-TNF-α
treatment although it can also be effective in pre-existing
Sweet syndrome (52, 53). Some isolated cases responded to
IL-1 inhibition (anakinra) (54, 55). Neutrophilic dermatoses
associated with auto-inflammatory disorders (e.g., Schnitzler
syndrome, Muckle-Wells syndrome) respond well to IL-1
inhibitors (56).
BULLOUS DISORDERS: BULLOUS
PEMPHIGOID (BP) AND OTHER BULLOUS
DISEASES
Remarkable improvements have been seen for omalizumab in
BP. A systematic review found 22 reported cases with 84%
complete responses. Anti-BP180 IgE antibodies correlate with
disease activity in BP supporting their pathogenic relevance (57).
IgE autoantibodies against BP180 and BP230 were found in,
respectively 21/36 (58.3%) and 18/36 (50%) BP sera (58). The
favorable safety profile of omalizumab makes it an attractive
treatment option for BP (59).
Rituximab (anti-CD20) also led to 85% complete responses
in BP (in 62 patients). Rituximab was associated with lower
recurrence rates and a longer disease-free period compared
to omalizumab (60). Patients that first did not respond to
omalizumab but improved using rituximab (61), but also cases
with improvement on omalizumab after failure to rituximab have
been published.
Development of BP using anti-TNF-α treatment can occur
sporadically although this link remains controversial. Both for
ustekinumab and secukinumab cases of successful treatment
of BP and new onset BP during treatment have been
described (62–65). IL-17 production by innate immune cells,
especially neutrophils, is characteristic in lesional BP skin. IL-17
upregulates matrix-metalloproteinase-9 and neutrophil elastase
expression which are involved in blister formation (66). Elevated
serum concentrations of IL-23 were confirmed in BP patients and
rising levels were associated with disease relapse. This pathway
could therefore be potentially interesting in BP (66).
Besides pemphigus, rituximab has been administered
successfully in other autoimmune bullous diseases. In a
retrospective cohort, mucous membrane pemphigoid (n= 14)
exhibited disease control in 85.7% (partial response: 64.3%,
complete response: 28.6%) (67). Similarly, some encouraging
data have been obtained in ocular cicatricial pemphigoid (68). A
meta-analysis showed that rituximab is also a promising option
in epidermolysis bullosa acquisita (69).
PSORIASIFORM DISORDERS: PITYRIASIS
RUBRA PILARIS
Off-label use of biologics has been extensively performed in PRP
given its high clinical and pathogenic similarity with psoriasis.
Anti-TNF-α, anti-IL-17 and anti-IL-12/23 treatments are all
effective with marked to complete responses ranging around
50–78%. Partial responses were seen in 11–25% of patients
and lack of response in 11–25% (70). Infliximab exhibited
superior results compared to adalimumab while ustekinumab
is currently most widely used for this disorder. Recent case
series on IL-17 inhibition (secukinumab and ixekizumab) show
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a fast clearance and limited risk of recurrence after therapy
withdrawal (71, 72). Nonetheless, treatment response is difficult
to predict due to the heterogeneity of the disease (73). Both
cases with progression using IL-17 inhibition that subsequently
improved using ustekinumab (74) as a patient with limited




The role of TNF-α producing macrophages in granuloma
formation points to a key role of this cytokine in granuloma
annulare. A summary of published cases showed that 20/26
patients with granuloma annulare responded to anti-TNF-α
treatment (75). Overall, these data support a high efficacy
of TNF-α inhibitors in granuloma annulare although well-
designed RCTs are missing. Nonetheless, granuloma annulare
has also been reported as a side effect of biologics including
adalimumab, infliximab and etanercept but also during treatment
with secukinumab (76–78).
MASTOCYTOSIS
Given its excellent efficacy in urticaria, the use of omalizumab
in other mast cell mediated diseases such as mastocytosis looks
promising. Most published cases report excellent efficacy on
systemic symptoms (e.g., gastrointestinal problems, pruritus).
Some interesting patients with resolution of cutaneous lesions
have been observed (79, 80). A multicenter RCT with 7 patients
receiving omalizumab and 9 placebo was conducted. After 6
months, improvement in French Association for the Initiatives of
Research on Mastocyte and Mastocytosis (AFIRMM) score was
higher in the omalizumab group (52–26 vs. 104–102) although
significance was not reached (81).
TOXIC EPIDERMAL NECROLYSIS
Being one of the most life-threatening skin disorders, treatment
of toxic epidermal necrolysis is extremely important. TNF-α has
been identified in the blister fluid and serum of TEN patients
(82). Most evidence is gathered from case series and case reports.
Nonetheless, the majority of cases show excellent responses with
improved outcomes compared to the expected mortality (83). An
interesting case series of 10 patients with excellent outcome using
etanercept was published (84). Adequate screening for infections
is necessary given the high prevalence of soft tissue infections (S.
aureus, P. aeruginosa, K. pneumoniae) (83). An RCT comparing
etanercept (n= 48) with corticosteroids (n= 43) showed a lower
mortality rate after etanercept (8.3%) compared to predicted
outcome (17.7%). The difference with the corticosteroid group
(16.3%) was not significant although the time for complete skin
healing was lower (85). Nonetheless, more than 50 cases have
been described developing TEN despite concurrent treatment
with TNF-α blockers.
LICHEN PLANUS
Lichenoid drug eruptions are a well-known side effect of TNF-
α blockade (86). Cutaneous and oral lichen planus, lichen
planopilaris and lichen striatus have all developed in patients
receiving anti-TNF- α treatment. Nonetheless, in some cases
of extensive lichen planus adalimumab showed improvement
and isolated cases of oral lichen planus and nail lichen planus
improved using etanercept (87–89). Despite some promising
reports, rituximab failed to show efficacy in a small trial with
five consecutive patients with erosive lichen planus (90). Data on
other biologics are very limited.
DISCUSSION
Several promising results have been obtained by the off-
label use of biologics and by pilot trials (Table 1, Figure 1)
although disappointing results can be equally important to
clarify the underlying pathogenic pathways. Failure of both
TNF-α inhibitors and IL-17A-blockers in alopecia areata and
vitiligo limits the involvement of these cytokines in the immune-
mediated destruction of skin cells (10, 11). However, the apparent
efficacy of TNF-α inhibitors in toxic epidermal necrolysis and
occasional cases of alopecia areata and vitiligo suggest that the
role of TNF-α is more complex (4, 7, 91). Alopecia areata and
vitiligo remain biologic orphan diseases although some exciting
cases have been published showing hair regrowth after initiation
of ustekinumab (13, 14).
Promising early data concerning the blockage of the IL-
23/IL17 pathway in HS confirm that this pathway is an important
initiator of a suppurative neutrophilic inflammation (19, 20,
22, 92). The benefit of blocking IL-17 in aphthosis is in
agreement with its defensive capacities against mucosal invasion
of pathogens and its protective actions to maintain epithelial
barrier integrity.
The results of the phase II trial of ustekinumab in lupus could
be a major breakthrough although phase III trials have to be
awaited. Increased IL-12 and IL-23 levels have been reported in
SLE patients and genetic research links the IL-12 pathway with
an increased susceptibility for SLE (29). In general, interferon
is considered the main driving factor in lupus. In contrast, the
efficacy of ustekinumab was independent of interferon levels
(29, 31, 32).
One of the most remarkable findings was undoubtedly
the impressive resolution of bullae in BP following the
administration of anti-IgE antibodies (59, 59, 60, 93, 94). This
confirms the pathogenic role of anti-IgE antibodies which seem
actively involved in the development of bullae. Mice injected
with IgE autoantibodies from BP patients in grafted human skin
developed erythema and infiltration of eosinophils in the skin
and ultimately histological dermal-epidermal separation (95).
Further studies on omalizumab in bullous pemphigoid seem of
particular value given its efficacy and improved safety profile
compared to the alternative options.
While current biologics cover mainly the Th17 pathway,
strong inhibition of important Th1 cytokines such as IFN-γ is
not (yet) available leading to disappointing results in vitiligo











































TABLE 1 | Biologics and their efficacy in off-label skin diseases.
Anti-TNF-α Anti-IL12/23 Anti-IL17 Anti-IL23 Anti-IL1 Anti-IgE Anti-CD20
Efficacy Evidence Efficacy Evidence Efficacy Evidence Efficacy Evidence Efficacy Evidence Efficacy Evidence Efficacy Evidence
Alopecia areata – CR + CR – PT
AE CR
Vitiligo –/(+) PT – PT
AE RCS
Hidradenitis suppurativa + RCT + PT + CR + RCT
Acne conglobata + CR
Lupus AE CR + RCT +/– PT, CR +/– RCT + CR, PT
– RCT
Dermatomyositis +/– RCT +/– CR + CR
Aphthosis/behcet + RCT + PT + CR + CR
Pyoderma gangrenosum + RCT + CR + CR
AE CR
Bullous pemphigoid AE CR AE CR AE CR + CR + CR
+ CR + CR
Pityriasis rubra pilaris + PT + PT + CR
Granuloma annulare + PT, CR
Toxic epidermal necrolysis + RCT AE CR
Lichen planus + CR – PT
AE CR + CR
Evidence: CR (white), case reports (at least 2 case reports); PT (gray), pilot trials; RCT (black), randomized controlled trials; RCS, retrospective cohort study; + (green), positive evidence; +/– (orange), unclear/conflicting results; – (red),
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FIGURE 1 | Summary of the involved cytokines in cutaneous disorders (Crossed interleukins: trials were conducted but failed). Mucosal ulceration involves a wide
range of cytokines and therefore biologics inhibiting different pathways (IL-1, TNF-α, and IL-17/23) result in improvement. Pityriasis rubra pilaris has a psoriasis-like
pathophysiology with a TNF-α stimulated production of IL-23 by dendritic cells. This results in the release of IL-17. Bullous pemphigoid is an antibody-mediated
disorder where both inhibition of B lymphocytes (e.g., rituximab) as binding of IgE-antibodies with omalizumab is efficacious. The pathophysiology of lupus is complex
with a possible driving role for IL-12 and IL-23. Mixed results for inhibition of B-lymphocytes with rituximab were obtained. TNF-α inhibitors are associated with
drug-induced lupus. In neutrophilic pustular disorders (pyoderma gangrenosum, acne, hidradenitis), the IL-17 pathway seems crucial with beneficial results if
cytokines of this pathway are targeted (IL-17, IL-23, and TNF-α). In alopecia areata and vitiligo, antibodies against TNF-α and IL-17 were disappointing. Some
evidence exists for a role of ustekinumab (IL-12/23) in alopecia areata. TNF-α and IL-12/23 can be targeted in granuloma annulare.
and alopecia areata. Dupilumab, a monoclonal antibody directed
against IL-4 and IL-13, developed for atopic dermatitis interferes
with key cytokines in the Th2 pathway and offers new possibilities
for off-label use. Case reports of good response to different
types of chronic itch including prurigo nodularis, uremic
pruritus and genital pruritus illustrate the interesting potential
of dupilumab (96–99). New development of alopecia areata
has been observed during treatment with dupilumab (100–102).
Nonetheless, patients with both atopic dermatitis and alopecia
areata treated with dupilumab have repeatedly demonstrated
hair regrowth (103–105). Furthermore, some isolated cases were
published with beneficial results in bullous pemphigoid (106),
eosinophilic annular erythema (107), and papuloerythroderma of
Ofuji (108).
Biologics have been linked to the occasional development
of alopecia areata, vitiligo, lupus, dermatomyositis and bullous
diseases. However, as we have learned from TNF-α antagonists
in psoriasis, this finding does not exclude their efficacy. Increased
serum or lesional levels of specific interleukins do not ensure the
efficacy of the corresponding biologic. As seen in alopecia areata
and vitiligo, numerous studies documented increased TNF-α and
IL-17 levels while the inhibition of both cytokines failed in these
disorders (10, 11). Unfortunately, the lack of convincing mouse
models for most dermatologic disorders limits the evidence that
can be obtained before conducting a clinical trial.
Getting biologics approved and reimbursed for these
new indications is another challenge. Weighing economic
implications vs. health improvement will remain a difficult
balance in the next decades. The rise of biosimilars may improve
access to off-label use in disorders which are unlikely to be of
economic interest due to their rare incidence or limited patients
with severe disease requiring biologics (109). An increased
appreciation and funding of investigator-initiated clinical
trials seem of particular relevance to explore the full capacity
of biologics.
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